joining of we to that team, will is am for our most credit just to and you since few Bio, transitioned by us past pipeline. for have I differentiated therapies years the our in Thanks, company overall successfully stage who the clinical a remarks this Passage This obtained begin company’s Stuart, morning. in all three successfully global advanced to months. proud talented multiple a and I In thank have committed my our our launch with regulatory authorizations highlighting two progress. report programs
with have includes supply strong highly foundation, the build manufacturing our out; which the two, of started Pennsylvania’s established; that integrated chain for a infants underpinned robust in with therapies continuing adults gene execution. who partnership corporate to rare executing therapy inspires are broad move pillars. diseases, program, devastating We and we the and and strategy, treatments. solid that a We to us neurological we are journey three, urgency which our gene our team position. four and and strong experienced our to University need develop suffer mission by four, pipeline ambitious who or our Their life-transforming cash One, GTP; is strategic with driven from desperately by XXXX
April On two patient our in than in IND first team, Gangliosidosis. trial efforts the for approvals. reflect partnership example, announced our the major infantile the of period company, These PBGMXX and GMX our of a of less Imagine-X our with for also For tremendous dosing and a recent accomplishments we patients, X, global months, we three milestone with of GTP. obtained for
continuing are our to other sites disease. on initial We dementia programs for program, GMX activating and sites focus our clinical additional frontotemporal Krabbe two in for and
our bodies ethics This clinical activate diligently trials that While we experiencing over includes working have committees, various site prioritized staffing openings. and COVID-XX at meeting are review impact site some hospitals. are delays to on levels or across sites the programs, to due with COVID-XX-related ours, also we investigation
upcoming updated our we situation, programs. stage the for Given the expected for milestones timelines have clinical the three clinical
our For quarter this in of GMX, second the trial Phase data Phase third in quarter. fourth the expect to now are the FTD-GRN report first now expecting safety this biomarker of year, trial initial patient in our Krabbe the patient enroll XX-day quarter first in we or We enroll I/II expect I/II to our in third to year. and and
expect lead ahead. key we our of that the we with at to Excellence, this, the and advocacy year and of genetic a key of status programs, establishing recruitment data these I clinical three review initiatives the Additionally, established of Today, first will mind highlighting free keep areas identification focus, in sites initial remain will aspects, our have support trial each to programs. Centers including important in planned raise of of on report screening, trial certain half to clinical of Patient and groups continents programs partnerships for be in forming awareness XXXX. to variety
are also keep their Before delving to into each like review program, I important mind. in which would to commonalities,
programs rare devastating monogenic three all conditions, CNS impact. address with First, lead
broad via disease the following we delivery CSF severely disorders of why, cisterna is using have a CNS is intra This data, conditions, manifestation, early or and rapid driven priority. and because ICM, ICM is supporting route achieves administered vessels all requires low modern CSF direct shortened. magna, preclinical survival blood our of for It delivery, symptom painless compared under is are to relatively therapies. while antibodies. anti-capsid again, and identification are advanced progression impact severe three CNS using the these delivery and onset, of For neuron the into patient IV support symptoms into to doses, to neuro-imaging patients made reduces disease neutralizing magna, anesthesia, the cisterna precise most while strong avoiding by and structures. direct a we systemic Since distribution. three our administration This
is being in at to reasons, these clinical use ICM to both gene administration adult for deliver used For and least in patients. CNS, seven is studies the other and therapy currently pediatric increasingly
need while our identify differentiated. programs where we raising and point both of vantage awareness From competing point, believe are possibility three all are to competition will treatments programs, these I are forward lead our bringing our out early highly for of for of disease programs areas that diseases, patients the Finally, there is patients. rare the in
pleased Gangliosidosis. dosed patient our GMX, to with our to for to support patients stress Turning treat in how healthcare and first their again, we the specifically begin to have trial, realize are us want in I extend to PBGMXX the our want potential patient of global Imagine-X the gratitude providers GMX family, to attention to and I helping
early rapid is infantile the on a disease, form no As study beyond PBGMXX, the of very current supportive disease late-onset focused cisterna single the options infantile open I/II with course our is subjects is a into with the in Imagine-X most administered The and treatment which reminder, Phase severe injection form, by magna, and care. trial trial global, label GMX. a a of
infantile Our for study will enroll GMX. late-onset two and infantile cohorts a with separate of early-onset four cohorts of total patients each,
improve this with aim allow the primary goal study is function quality to infantile and ultimate safety Our develop tolerability of will is cohorts. dose that transformative and data a trial assess gene potential of and initial patients life GMX. for developmental early our therapy survival progress preserve escalation the into with and to for neurologic to from The
activity enzyme We of because is greater also plan serum. earlier levels severity generally know and lower disease This CSF we activity. correlate important, to with in beta-gal and the measure onset that of beta-galactosidase
cohort data, in to of of fourth and we of As I initial beta-gal earlier, first patients infantile report late XX-day XXXX. enzymatic safety the mentioned for activity expect tolerability the and quarter
As in been we reported press has our States. dosed patient United last in month, first our release the
in to are GMX of also received open due on sites we and with countries Turkey, in have founder’s incidence the clearance plan help a will enrollment. very Brazil globally, Canada, to focused which and also XX Brazil. effect, patient recently, and like which higher UK, is We regulatory a We there believe
Invitae through New and Additionally, such pilot we program. with up York’s patient ones are we identification ScreenPlus ramping have the as efforts partnerships,
and we us This patients program. enrollment will We support have storage and investigators coordinators confident advocacy immensely these be in patient useful for that Centers lysosomal helping also specializing able with in network groups comprehensive Excellence and a identify approach has cohort, been ongoing in initial at our our site to disorders. of efforts strong are built to
disease. in Now, turning our Krabbe program attention to the PBKRXX
received our life two We initiate regulatory brain of have rapidly, United peripheral and nervous MHRA clearance Health this disease for FDA, Canada. both and expectancy and program system, from in clinical Krabbe damaging Kingdom, years. in the the the to progresses resulting a trial only
that Our global an to label disease. Phase with of infantile in ICM AAV will open deliver GAL-C Krabbe an capsid I/II trial, dose the patients use via GALax-C, escalation early enzyme study will PBKRXX be
data initial of dose GALax-C we for safety first quarter As third will that XX-day will we half biomarker discussed, and patient XXXX. in the safety of first report the and our in we expect study and XXXX,
goal Our early disease. the first study for is of patients safe with infantile that to Krabbe demonstrate PBKRXX is
and demonstrate dose dosage the our an the age this second escalation look increase very We for to Our similar CSF will hope design to an program, portion the in group. by increase The separated GMX goal is in serum. GAL-C. of demonstrate biomarker and trial both in to
enrolling four age each a dose enrollment. cohorts separate begin on and with of We cohorts will of based three escalation total subjects
occurring increased function single brain of canine motor We are in beneficial our of in in you, nerve reduced To disabling it These neuropathy causes gene animal on disease. the specially agent, functional are normalized remind to levels, it encouraging, resulted GAL-C translates of peripheral cytosine severe optimistic myelination, inflammation, improved deficits brain because humans, the survival. potential Krabbe a single that on CSF a an effects activity, injection a nerve potentially the peripheral naturally AAV peripheral conduction normalization if treat velocity, reduced canine ICM will GAL-C based and as about model, Krabbe therapy carrying models. vector transformative
Newborn screening to best diseases the early babies treatment, pediatric pre is hopefully important where it like is symptomatic ideal to especially outcomes. identify or rare for Krabbe, produce for
onset identification development Krabbe For we testing state-by-state the and with support groups Krabbe stakeholders, and key positives can are refining support we early the between babies of of believe rate differentiating versus screening, additional screening accurate risk reduce early onset and to disease We of newborns in by Krabbe newborn to high newborn that Krabbe working of aid false screening, later developing newborn advocacy at disease. with Krabbe disease. and
lysosomal We as programs. also to expanded disease clinical counseling, its program, to our access have as Krabbe provides Invitae, collaboration disease which testing genetic free include well genetic with appropriate testing and to referrals trial in
Next, PBFTXX, trial for treatment with our global Canada. for granulin and This clinical program, temporal has let’s global frontal United authorizations Phase called, trial the dementia now clinical clinical the UpliFT-D, mutations. initiate discuss sites trial in States third regulatory of to I/II
causes many As Dementia. of the common is know, of you one early of onset FTD more
on UpliFT-D gene deficiency To for disease occurs are in where progranulin. because We the the GRN patients trial. specifically of mutations the of identify focused help a causing FTD-GRN
well reporting enrollment. leading about treatment testing which InformedDNA genetic we with that estimated of We deficiency individualized a It translates of of providing is with approaches an as have important early designing by anticipate now and protein. counseling first XX% a vector, Administered and of United is We functional FTD. for facilitate FTD the half third which mutation, X% second subjects FTD-GRN. States. progranulin. are encoding the patients about to safety injection genetic to delivered gene and of label trial be in gene utilizes program offering identification to later in patients XXXX as brain quarter an initial the symptomatic will mutations, will our have XXXX for entered first in with year, by XXXX. UpliFT-D AAVX the biomarker cisterna patient of the the a dose The an caused free into patients This FTD diagnosed in into potential PBKRXX, clinical or XX-day single in study step inherited who granulin GRN to the in with to an been magna dosing to this progranulin support escalation open collaboration
patients for is Our demonstrate this first is goal for safe to with that study FTD-GRN. PBFTXX
levels and go an to we of second will during relates to into the is FTD. we demonstrate webinar role progranulan it deeper Our XX, scheduled goal in have CSF. progranulan increased as which On May R&D
data, see we’ll design review also trial. will we trial supporting We what from our the our and and plans the clinical development preclinical discuss clinical hope to
are As successful outset, the at advanced most on three the sharply I mentioned focused year our programs. we clinical of this development
are and broad R&D decades. CNS with is rare focus have preclinical Officer. pharmaceutical in with We as Chief our Research recently expanding pipeline deep the experience. also neuroscience experience Salinas, our worked He and to on on more in company’s extensive and brings for Eliseo three focused diseases, industry we also in our lead and Having advancing has these GTP. and well To biotech excited are Eliseo Development truly efforts appointed which than disorders. collaboration aligned rare
other capabilities and our dedicated of Catalent clinical distribution components gene and manufacturing our for at relationships Jersey this established manufacturing our R&D our are company’s suite robust we advance success. opening manufacturing to chain we control As quarter. pipeline, New site supply To scalable and forward complement in look important our flexible supply our therapy,
We company’s of our to Board also pleased Maxine have Gowan are added to Directors.
and financial give clinical And As at and period over company public Maxine over with co-founded in as the leadership significant stage brings roles led evolve GlaxoSmithKline call variety to leadership that and a expertise of Rich development company to we of turn years. continue biotech clinical XX served a I’ll a a update. a to startup company. having
